ClinicalTrials.gg
RecruitingNCT05653635ReciDOPAUpdated Feb 4, 2026

Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

A Phase 2 interventional study of Simultaneous-integrated boost with IMRT in Glioblastoma, sponsored by Centre Paul Strauss. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Centre Paul Strauss · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Glioblastoma with a site in France — 35 open to participants now, 51 under way, 9 of them phase 3. Glioblastoma · France.

Planned enrollment
84th of 131
54 · median 80
Started
2026
with 7 others
Phase 2
33 of 150
6 open now
Primary completion
2028-09
later than 37 of 50 live
Registered
119th of 150
by date

Among the 150 studies in Glioblastoma with a site in France, this one is the 84th largest by planned enrollment of the 131 interventional ones that give a count, is one of 8 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 37 of the 50 other live ones, and was the 119th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

35 of the 150 studies in Glioblastoma with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Glioblastoma with a site in France, or all of them as a file.
02

Study summary

ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.

Read the detailed description

Glioblastoma (GBM) is the most common cerebral tumor in adults. Despite well-conducted treatments including surgery, chemo-radiotherapy and chemotherapy according to the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) protocol, recurrences remain unavoidable within approximately 6 months and the overall survival rate of patients at 5 years is inferior to 10%.

In case of recurrence, a second surgery, radiotherapy under stereotaxic conditions, bevacizumab or other innovative techniques have been proposed. However, they are not yet considered as reference treatments, due to the absence of therapeutic trials definitively proving their efficacy.

Evaluation of GBM progression is based on MRI, corticosteroid intake and clinical status.However, positron emission tomography (PET) is an extremely relevant examination for differentiating between true progression and pseudo-progression. Indeed, an increase in the transfer of amino acids in 18 F-dihydroxyphenylalanine (FDOPA)-PET strongly suggests a recurrence. A local treatment can then be proposed by favoring surgery or, as an option, radiotherapy under stereotactic conditions. However, this treatment, even if it is well tolerated, has an efficacy which could be improved.

Often proposed option to improve efficacy of this radiation technic consists in increasing the dose of irradiation. This dose increase is often limited by the tolerance of nearby healthy tissue. It could however be possible with coupled techniques of intensity modulation and stereotaxy within the framework of an integrated boost (Simultaneous Integrated Boost - SIB). At each radiation session, the dose delivered to the tumor volume would be increased in the metabolic volume (BTV) detected by FDOPA-PET.

The objective of this study is to evaluate, in patients with recurrent glioblastoma, the efficacy of a dose increase using an SIB in a volume delineated with FDOPA-PET.

03

Conditions studied

  • Glioblastoma

Browse trials for

Keywords

  • Glioblastoma
  • Simultaneous Integrated Boost
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • Glioblastoma, World Health Organization (WHO) grade IV, proven
  • Performance status 0, 1 or 2
  • Neurological status ≥ 2
  • Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm)
  • Radiological proven recurrence according to 1 and 2 criteria, Wen et al
  • Remaining node after partial surgery post-recurrence
  • 1 to 3 recurrence site(s) \< 35 mm in wide axis and separated by at least 5 mm
  • Volume of each lesion \< 35 mL
  • Distance between recurrence node(s) and optic nerves (left and right), chiasma and/or cerebral trunk > 10 mm

Exclusion criteria

Exclusion Criteria:

  • Patient with to MRI or PET
  • Glioblastomatose
  • Pregnancy or breastfeeding
  • Patient that do not understand French
  • Patient without affiliation to the national or local social security
  • Patients not able to comply to the protocol assessments for geographic, social or psychological reasons
  • Minor or patients placed under guardianship or supervision
  • Patients deprived of liberty
  • Patients placed under judicial protection
  • Patients that are not able to express their consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Simultaneous-integrated boost with Intensity-modulated radiation therapy (IMRT)

    * Planning Target Volume (PTV) 37,5 Gray (Gy): 37,5 Gy in 6 fractions of 6,25 Gy at the rate of one fraction each 2 days * Prescription isodose line (PIL) at 80%, corresponding to 30 Gy as total dose, or 5 Gy per fraction * PTV SIB 45 Gy: 45,0 Gy in 6 fractions of 7,50 Gy at the rate of one fraction each 2 days * PIL at 80% corresponding to 36 Gy as total dose, or 6 Gy per fraction

    Radiation: Simultaneous-integrated boost with IMRT

  • No intervention
    Standard IMRT

    * PTV 37,5 Gy: 37,5 Gy in 6 fractions of 6,25 Gy at the rate of one fraction each 2 days * PIL at 80%, corresponding to 30 Gy as total dose, or 5 Gy per fraction * No SIB

Interventions

  • RadiationSimultaneous-integrated boost with IMRT

    Simultaneous-integrated boost guided by FDOPA-PET

06

What researchers measure

Primary outcomes

  1. Efficacy of simultaneous-integrated boost with IMRT guided by FDOPA PET on Recurrence free survival in patient with recurrent glioblastoma

    Recurrence free survival: interval between the date of inclusion in the trial until the date of recurrence of irradiated site (or one of the irradiated sites, in case of multiple irradiation)

    Time frame: up to 24 months

Secondary outcomes

  1. Percentage of recurrence of irradiated sites

    Number of sites with recurrence over the number of irradiated sites

    Time frame: up to 24 months

  2. Characterization of recurrence sites: classified either as distant, marginal or in-field

    Recurrence will be described according to their localisation by comparing images at recurrence with the images used for dosimetry. A recurrence will be defined as " distant" is it appears outside of 80% isodose, as "marginal" if it cuts 80% isodose and as "in-field" if it is completely located in 80% isodose. The 80% isodose is the reference isodose used for radiation therapy prescription.

    Time frame: up to 24 months

  3. Percentage of Recurrence free survival at 6 months

    Interval between the date of inclusion in the trial until the date of recurrence of irradiated site (first recurrence, in case of multiple irradiation). Patients that are alive without recurrence at the end of the tiral will be censored

    Time frame: At 6 months

  4. Percentage of Recurrence free survival at 12 months

    Interval between the date of inclusion in the trial until the date of recurrence of irradiated site (first recurrence, in case of multiple irradiation). Patients that are alive without recurrence at the end of the tiral will be censored

    Time frame: at 12 months

  5. Overall survival

    Interval between the date of inclusion in the trial until the date of death whatever the cause. Patients that are alive without recurrence at the end of the tiral will be censored

    Time frame: From date of inclusion until the date of death from any cause, assessed up to 72 months

  6. Tolerance of re-irradiation

    Recording of toxicities (according to Common Terminology Criteria for Adverse Events v5 criteria) at each follow-up visit

    Time frame: up to 24 months

  7. Characterization of PET parameters at recurrence and compare them to baseline parameters with SUV max value

    Standardized Uptake Value (SUV) max

    Time frame: up to 24 months

  8. Characterization of PET parameters at recurrence and compare them to baseline parameters with SUV mean value

    SUV mean

    Time frame: up to 24 months

  9. Characterization of PET parameters at recurrence and compare them to baseline parameters with SUV peak value

    SUV peak

    Time frame: up to 24 months

  10. Quality of Life at 2 months measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    Quality of life will be measure with the Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 2 months

  11. Quality of Life at 2 months measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    Quality of life will be measured with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 2 months

  12. Quality of Life at 4 months measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    Quality of life will be measure with the Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 4 months

  13. Quality of Life at 4 months measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    Quality of life will be measured with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 4 months

  14. Quality of Life at 6 months measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    Quality of life will be measure with the Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 6 months

  15. Quality of Life at 6 months measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    Quality of life will be measured with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 6 months

  16. Quality of Life at 12 months measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    Quality of life will be measure with the Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 12 months

  17. Quality of Life at 12 months measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    Quality of life will be measured with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 12 months

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Sep 2028, 30 months later.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 30 months is below that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 16, 2022
StartEst.
Mar 1, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05653635
Lead sponsor
Centre Paul Strauss
Collaborators
Centre Georges François Leclerc
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Mar 1, 2026 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Feb 4, 2026

Study contacts

Anne ANTHONY
Contact
promotion-rc@institut-strauss.fr
(0)388252413 ext. 33
MANON VOEGELIN
Contact
promotion-rc@institut-strauss.fr
(0)3 68 33 95 23 ext. 33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion